Thiazolidinedione insulin sensitizers alter lipid bilayer properties and voltage-dependent sodium channel function: implications for drug discovery

Radda Rusinova, 1 Karl F. Herold, 2,5 R. Lea Sanford, 1 Denise V. Greathouse, 4 Hugh C. Hemmings Jr., 2,3 and Olaf S. Andersen 1

1 Department of Physiology and Biophysics, 2 Department of Anesthesiology, and 3 Department of Pharmacology, Weill Cornell Medical College, New York, NY 10065
4 Department of Chemistry and Biochemistry, University of Arkansas, Fayetteville, AR 72701
5 Department of Anesthesiology and Intensive Care Medicine, Campus Charité Mitte, 10117 Berlin, Germany

The thiazolidinediones (TZDs) are used in the treatment of diabetes mellitus type 2. Their canonical effects are mediated by activation of the peroxisome proliferator–activated receptor γ (PPARγ) transcription factor. In addition to effects mediated by gene activation, the TZDs cause acute, transcription-independent changes in various membrane transport processes, including glucose transport, and they alter the function of a diverse group of membrane proteins, including ion channels. The basis for these off-target effects is unknown, but the TZDs are hydrophobic/amphiphilic and adsorb to the bilayer–water interface, which will alter bilayer properties, meaning that the TZDs may alter membrane protein function by bilayer-mediated mechanisms. We therefore explored whether the TZDs alter lipid bilayer properties sufficiently to be sensed by bilayer-spanning proteins, using gramicidin A (gA) channels as probes. The TZDs altered bilayer elastic properties with potencies that did not correlate with their affinity for PPARγ. At concentrations where they altered gA channel function, they also altered the function of voltage-dependent sodium channels, producing a prepulse-dependent current inhibition and hyperpolarizing shift in the steady-state inactivation curve. The shifts in the inactivation curve produced by the TZDs and other amphiphiles can be superimposed by plotting them as a function of the changes in gA channel lifetimes. The TZDs’ partition coefficients into lipid bilayers were measured using isothermal titration calorimetry. The most potent bilayer modifier, troglitazone, alters bilayer properties at clinically relevant free concentrations; the least potent bilayer modifiers, pioglitazone and rosiglitazone, do not. Unlike other TZDs tested, ciglitazone behaves like a hydrophobic/amphiphile and alters the gA monomer–dimer equilibrium by more than one mechanism. Our results provide a possible mechanism for some off-target effects of an important group of drugs, and underscore the importance of exploring bilayer effects of candidate drugs early in drug development.

INTRODUCTION

The thiazolidinediones (TZDs; see Fig. 1) are peroxisome proliferator–activated receptor γ (PPARγ) agonists used in the treatment of type 2 diabetes mellitus to improve target cell insulin sensitivity (Hulin et al., 1996). TZDs reduce plasma triglyceride, fatty acid, and insulin levels, increase HDL cholesterol levels, and promote adipocyte differentiation (Hulin et al., 1996; Fujiwara and Horikoshi, 2000; Sarafidis, 2008)—effects that are mediated by PPARγ-regulated gene transcription.

In addition to the PPARγ-dependent effects, TZDs have off-target effects that do not appear to involve changes in gene transcription. These effects include acute changes in cellular glucose uptake, inhibition of L-type voltage-dependent calcium channels, KATP channels, and voltage-dependent potassium channels, as well as inhibition of bile acid transport (Table 1).

Many off-target TZD effects involve membrane proteins, which are sensitive to changes in their membrane environment (Lee, 2004; Andersen and Koepp, 2007; Marsh, 2008; Lundbæk et al., 2010a), and amphiphiles tend to be potent modifiers of membrane protein function at the concentrations where they alter lipid bilayer properties (Hwang et al., 2003; Lundbæk et al., 2004, 2005, 2010a; Artigas et al., 2006; Søgaard et al., 2006; Bruno et al., 2007; Ingólfsson et al., 2007). Because the TZDs are amphiphiles, we explored whether they alter lipid bilayer properties and thereby could modulate membrane protein function.

The “nonspecific” regulation of membrane protein function by amphiphiles occurs because of the hydrophobic
and energetic coupling between bilayer-spanning proteins and their host lipid bilayer (Fig. 2 A).

The insertion of a protein into a lipid bilayer will locally perturb the bilayer organization to deform the bilayer, which incurs an energetic penalty (the bilayer deformation energy, $\Delta G_{\text{def}}$). The difference in bilayer deformation energy between different conformations (denoted I and II) is the bilayer contribution ($\Delta G_{\text{bil}}^{\text{II}}$) to the free energy difference between I and II:

$$\Delta G_{\text{tot}}^{\text{II}} = \Delta G_{\text{prot}}^{\text{II}} + (\Delta G_{\text{def}}^{\text{II}} - \Delta G_{\text{def}}^{\text{I}}) = \Delta G_{\text{prot}}^{\text{II}} + \Delta G_{\text{bil}}^{\text{II}}.$$  \hspace{1cm} (1)

Because $\Delta G_{\text{def}}$, and thus $\Delta G_{\text{bil}}^{\text{II}}$, varies as a function of the bilayer physical properties (thickness, intrinsic monolayer curvature, and the associated elastic moduli), the protein’s conformational equilibrium will vary as a function of changes in the host bilayer properties (e.g., Lundbæk and Andersen, 1994; Ashrafuzzaman et al., 2006; Lundbæk et al., 2010a):

$$\frac{n_{\text{II}}}{n_{\text{I}}} = K^{\text{I} \rightarrow \text{II}} = \exp \left[ \frac{-\Delta G_{\text{tot}}^{\text{II}}}{k_B T} \right] = \exp \left[ \frac{-\Delta G_{\text{prot}}^{\text{II}} + \Delta G_{\text{bil}}^{\text{II}}}{k_B T} \right],$$  \hspace{1cm} (2)

where $n_{\text{I}}$ and $n_{\text{II}}$ denote the surface densities of the proteins in state I and II, $K^{\text{I} \rightarrow \text{II}}$ is the equilibrium constant for the I$\leftrightarrow$II equilibrium, $k_B$ is Boltzmann’s constant, and $T$ is the temperature in Kelvin.

When amphiphiles adsorb at the bilayer–solution interface, they alter many bilayer properties, including the intrinsic monolayer curvature (Seddon, 1990; Lundbæk et al., 2005) and bilayer elastic moduli (Evans et al., 1995; Zhelev, 1998), which will alter $\Delta G_{\text{def}}$ (Fig. 2 B).

| TZD         | PPARγ EC$_{50}^{a}$ | Off-target and effect                            | EC$_{50}^{b}$ | Reference                      |
|-------------|---------------------|--------------------------------------------------|---------------|--------------------------------|
| Troglitazone | 0.5                 | ATP-sensitive potassium channel $K_{\text{ATP}}$ | 0.7           | Lee et al., 1996              |
|             |                     | L-type calcium channels                           | 3–4           | Nakamura et al., 1998         |
|             |                     | Ca$^{2+}$-activated potassium channel BK$_{\text{Ca}}$ | 20–30         | Knock et al., 1999; Stowers et al., 2000 |
|             |                     | Delayed rectifier potassium channel Kv1.3      | 3             | Ahn et al., 2007              |
|             |                     | Acute glucose transport                           | 3$^c$         | Preininger et al., 1999       |
|             |                     | Na$^+$/$\text{H}^+$ exchange                     | 10$^c$        | de Dios et al., 2001          |
|             |                     | Bile transport (bile salt export pump)          | 4             | Funk et al., 2001;            |
|             |                     |                                                   | 10$^c$        | Snow and Moseley, 2007        |
| Rosiglitazone | 0.06–0.09           | Voltage-dependent Ca$^{2+}$ current             | 2$^c$         | Knock et al., 1999            |
|             |                     | Ca$^{2+}$-activated potassium channels, BK$_{\text{Ca}}$ | 20$^b$       | Knock et al., 1999; Stowers et al., 2000 |
|             |                     | Delayed rectifier potassium channel Kv1.3      | 18            | Ahn et al., 2007              |
|             |                     | Bile transport                                   | 10$^c$        | Snow and Moseley, 2007        |
| Pioglitazone | 0.5                 | L-type calcium channels                           | 45            | Nakamura et al., 1998         |
| Ciglitazone  | 3–23                | Ca$^{2+}$-activated potassium channel BK$_{\text{Ca}}$ | 16            | Stowers et al., 2000          |
|             |                     | Store-operated calcium$^+$ channels              | 30$^c$        | Kim et al., 2005; Epstein et al., 2009 |
|             |                     | Bile transport                                   | 5$^c$         | Snow and Moseley, 2007        |

$^a$Henke et al., 1998.
$^b$Nominal concentrations, not accounting for drug distribution.
$^c$Effective concentration.
Changes in bilayer properties will alter membrane protein function when $\Delta G^{\text{tot}}_{\text{lip}}$ is a significant ($>k_bT$) contribution to $\Delta G^\text{tot}$, in which case changes in $\Delta G^\text{tot}$ will alter the energetics and kinetics of the I$\leftrightarrow$II equilibrium. This may provide a mechanistic basis for the widely observed “membrane effects” of many drugs (Seeman, 1972), including the TZDs.

To explore whether the TZDs alter lipid bilayer properties, we used the gramicidin A (gA) channels as probes (Andersen et al., 2007; Lundbæk et al., 2010a). gA channels are dimers (Bamberg and Läuger, 1973; Veatch et al., 1975), which form by the transmembrane dimerization of nonconducting single-stranded $\beta^{6.3}$-helical subunits that reside in each bilayer leaflet (O’Connell et al., 1996). The kinetics of gA channel formation and disappearance is described by Bamberg and Läuger (1973), Zingsheim and Neher (1974), and Rokitskaya et al. (1996):
force ($F_{\text{sw}}$) on the dimer, and the rate constant for dimer dissociation varies with changes in $F_{\text{sw}}$ (e.g., Lundbæk et al., 2010a). The adsorption of amphiphiles at the bilayer–solution interface alters lipid bilayer elastic moduli and the monolayer-intrinsic curvature, which in turn alters $F_{\text{sw}}$. These changes are observed as increased or decreased gramicidin channel lifetimes and appearance frequencies (Fig. 2D).

The TZDs alter lipid bilayers, with a rank order consistent with previous reports showing troglitazone as the most potent inhibitor of ion channel function (Knock et al., 1999; Ahn et al., 2007). They also inhibit voltage-dependent sodium channels (NaV). Similar to other amphiphiles (Lundbæk et al., 2005), the TZDs cause a hyperpolarizing shift in the steady-state availability curve. The concentration dependence of the TZDs’ effects on NaV is similar to that for gA channels, and the correlation between the TZD effects on gA and NaV channels can be superimposed on the relation observed for other amphiphiles (Lundbæk et al., 2005), suggesting that some TZD off-target effects are mediated by changes in bilayer properties.

**MATERIALS AND METHODS**

**Gramicidin experiments**

### Materials.
1. 1,2-dioleoyl-sn-glycero-3-phosphocholine (DC18:1,PC).
2. 1,2-dioleosyl-sn-glycero-3-phosphocholine (DC18:1,PC).
3. 1,2-dierucoyl-sn-glycero-3-phosphocholine (DC16:0,PC), and cholesterol were from Avanti Polar Lipids, Inc. n-Decane (99.9% pure) was from ChemSampCo. Troglitazone, rosiglitazone, and ciglitazone were from Avanti Polar Lipids, Inc.
4. 1,2-dioleosyl-sn-glycero-3-phosphocholine (DC18:1,PC), and cholesterol were from Avanti Polar Lipids, Inc. n-Decane (99.9% pure) was from ChemSampCo. Troglitazone, rosiglitazone, and ciglitazone were from Avanti Polar Lipids, Inc. n-Decane (99.9% pure) was from ChemSampCo. Troglitazone, rosiglitazone, and ciglitazone were from Avanti Polar Lipids, Inc.
5. Fluorescence quench measurements. This method has been described elsewhere (Ingolfsson and Andersen, 2010; Ingolfsson et al., 2010). In brief, DC18:1,PC bilayers were formed with 13 α-amino acid analogue, des-D-Val-Gly-gA (gA(13)) and two 15-α-amino acid analogues of opposite helix sense, [Ala]15-gA (AgA(15)) and [D-Ala1]15-gA (AgA(15)), and a chain-extended 17-amino acid analogue, endo-Ala4-D-Ala9-gA (gA(17)), were synthesized and purified as described previously (Graehl et al., 1999). Their sequences are listed in Table S1.

### Single-channel current measurements.

Planar lipid bilayers were formed at 25 ± 1°C using 20 mg/ml suspensions of DC18:1,PC, DC16:0,PC/cholesterol (1:1 molar ratio), or DC18:1,PC in n-decane across a 1–1.5-mm opening in a Teflon partition separating two 2.5-ml compartments. The channel and electrode solutions were 1.0 M NaCl and 10 mM HEPES, pH 7. Single-channel measurements were done at ±200 mV using a patch-clamp amplifier (3900A; Dagan Corp.) and the bilayer punch method (Andersen, 1987; Kapoor et al., 2008). The current signal was filtered at 2 kHz, sampled at 20 kHz, and digitally filtered at 500 Hz. Single-channel current transitions were identified as described previously (Andersen, 1983) using software written in Visual Basic (Microsoft). The gA analogues were added to both sides of the bilayer. In most experiments, we used two analogues of different length and helix sense, which allowed us to explore the role of hydrophobic mismatch. After control records were obtained, we added TZD from stock solutions (prepared in DMSO) to each side of the bilayer, stirred for 1 min, and equilibrated for 10 min. The DMSO concentration never exceeded 0.7% (vol/vol), which by itself has no effect on bilayer properties (Ingolfsson and Andersen, 2010).

Single-channel lifetimes ($\tau$) were determined by fitting a single-exponential distribution ($N/\tau = \exp(-t/\tau)$, where $N$ is the number of channels with lifetimes longer than time, $t$, to the survivor histograms of the lifetime distributions using Origin 6.1 (OriginLab). The reported results are the averages of three to five experiments, each with at least 300 events. Changes in channel appearance frequency ($f$) are based on single-channel recordings (>5 min) immediately before and immediately after adding the TZDs. Only experiments where the bilayer remained intact after TZD addition were used. The results are reported as mean ± SD; in case there are only two observations, the results are reported as mean ± range. Relative lifetime and appearance frequency changes were obtained by normalizing the values just after to those just before adding the TZD.

From the changes in the time-averaged channel density ($f$) one can calculate the changes in the channel dimerization constant ($K_D$) as (Hwang et al., 2003):

$$\frac{f_{\text{TZD}}}{f_{\text{ctrl}}} \tau_{\text{TZD}} = \frac{K_D,\text{TZD}}{K_D,\text{ctrl}} \frac{k_{\text{off},\text{ctrl}}}{k_{\text{off},\text{TZD}}} \frac{[M]_{\text{ctrl}}}{[M]_{\text{TZD}}}$$

where the subscripts “ctrl” and “TZD” indicate the absence and presence of the TZD, and the third equality holds in the limit $[M] \gg [D]$ (when [M] is approximately constant). One can then calculate the changes in the free energy of dimerization ($\Delta \Delta G^{M-D}_D$) and, if the TZDs do not alter $\Delta \Delta G^{M-D}_D$, the changes in $\Delta \Delta G^{M-D}_{\text{ctrl}}$:

$$\Delta \Delta G^{M-D}_{\text{ctrl}} = -\frac{k_BT}{\Delta \Delta G^{M-D}_D} \ln \left( \frac{K_D,\text{TZD}}{K_D,\text{ctrl}} \right) = -k_BT \ln \left( \frac{f_{\text{ctrl}} \tau_{\text{ctrl}}}{f_{\text{TZD}} \tau_{\text{TZD}}} \right) = \Delta \Delta G^{M-D}_{\text{ctrl}}$$

where the right-most relation holds when $\Delta \Delta G^{M-D}_{\text{prot}} = 0$.

The capacitance of DC18:1,PC bilayers (area, ~1.5 mm²) was measured using the current response to a 2.5-Hz saw tooth potential of 10-mV peak-to-peak amplitude (Lundbæk et al., 1996).

### Fluorescence quench measurements.

This method has been described elsewhere (Ingolfsson and Andersen, 2010; Ingolfsson et al., 2010). In brief, DC18:1,PC bilayers were formed in chloroform and dried and rehydrated in a fluorescent (ANTS) buffer. Large unilamellar vesicles were prepared by passing the lipid suspension through a 0.1-μm membrane using a mini-extruder (Avanti Polar Lipids, Inc.), and extravesicular ANTS was removed using a desalting column (PD-10; GE Healthcare). ANTS-loaded vesicles were incubated with gA for 24 h at 12°C. The rate of ANTS fluorescence quenching by the gA channel–permeant Tl⁺ was recorded with a stopped-flow spectrophotometer (SX.20; Applied Photophysics) with dead time of <2 ms. Samples were excited at 352 nm, and the fluorescence signal above 455 nm was recorded. Vesicles were incubated with the TZD for 10 min at 25°C before measuring the quenching rate. TZDs are hydrophobic and cross the cell membrane to reach PAR; they likewise will equilibrate between the inner and the outer bilayer leaflets. Nine mixing reactions were done with each sample. Each reaction was analyzed separately using MATLAB v7.9 (The MathWorks Inc.). Quenching rates were determined by fitting the first 2–100 ms of the fluorescence time course for the individual reactions with stretched exponential (Berberan-Santos et al., 2005):

$$F(t) = F(\infty) + (F(0) - F(\infty)) \cdot \exp \left\{ \left( t / \tau_0 \right)^\beta \right\}$$

where $F(t)$ denotes the fluorescence intensity as a function of time, $t$, $\tau_0$ is a parameter with units of time, and $\beta$ ($0 < \beta \leq 1$) is a measure of the dispersity of the sample. We then determined the
The average quenching rate is the average of these rates. The reported values are averages of the quenching rates, normalized to rate in the absence of TZDs, for three or more experiments.

**Isothermal titration calorimetry.** Heats of adsorption were measured using an isothermal titration calorimeter (Auto-iTC2000; Microcal Inc.) with 200-µl sample cell volume and 40-µl syringe volume. Large unilamellar DC181PC or DG18:1PC vesicles were prepared as described above, with the following modifications: the lipid rehydration buffer (150 mM NaNO₃ and 15 mM HEPES, pH 7) did not contain ANTS, and the vesicles were not incubated with gA. TZDs were diluted from DMSO stocks with the lipid rehydration buffer. The DMSO concentration in the lipid vesicle solution was adjusted to match the TZD-containing solution.

The lipid vesicle solution was in the syringe, and the TZD solution was in the sample cell. Titration of lipid vesicles into the TZD solution was done with 2-µl injections (the first 0.2-µl injection was not taken into account during analysis). The 150 s interval between each injection allowed the signal to return to the baseline and was sufficient for equilibration of TZDs between the inner and outer bilayer leaflets. After 19 injections of 3 mM lipid into 30 µM troglitazone, or 10 mM lipid into 200 µM rosiglitazone, the TZD was considered to be bound to the lipid vesicles when the heat generation in subsequent injections became constant. (Gigilizone and pioglitazone did not produce a measurable signal.) To control for heat of dilution of buffer and lipid vesicles, lipid vesicles were injected into a TZD-free buffer solution. The enthalpy per injection was determined from the area under the titration curve in the sample cell. Titration of lipid vesicles into the TZD was achieved by injecting 30 µM troglitazone, or 10 mM lipid into 200 µM rosiglitazone, with 15 mM 130 NaCl, 2 CaCl₂, 2 MgCl₂, 10 TEACl, and 5 mg/glucose, adjusted to pH 7.4 (with NaOH), and 310 mOsm/kg H₂O (with sucrose).

Voltage-clamp recordings were done at room temperature (23–24°C) using a patch-clamp amplifier (Axopatch 200B; Molecular Devices) with a sampling rate of 20- and 5-kHz low-pass filter. Recording pipettes were pulled from borosilicate glass capillaries (Sutter Instrument) on a puller (P-97; Sutter Instruments) and fire-polished. The pipettes were filled with a solution containing (in mM): 120 CsF, 10 NaCl, 10 HEPES, 10 EGTA, 10 TEACl, 1 CaCl₂, and 1 MgCl₂, adjusted to pH 7.3 (with CsOH), and 310 mOsm/kg H₂O (with sucrose). The pipettes had a tip resistance of 1.5–2.5 MΩ. The access resistance, 2–4 MΩ, was further decreased using 70–80% series resistance compensation. The initial whole cell seal resistance was 2–4 GΩ, and recordings were discarded if the resistance dropped below 1 GΩ. Liquid-junction potentials were not corrected. Capacitive current transients were electronically cancelled with the internal amplifier circuitry, and leak currents were digitally subtracted online using the P/4 protocol (Bezanilla and Armstrong, 1977).

The TZDs dissolved in DMSO were diluted in the external perfusion buffer to their final concentration before experiments the same day. Final DMSO concentrations did not exceed 0.7% (vol/vol). (1% DMSO has no effect on activation or inactivation; not depicted.) The perfusion system consisted of Teflon tubing connected to a 200-µm diameter perfusion pipette positioned in close proximity to the patch-clamped cell. The perfusion rate was ~0.2 ml/min and controlled by a pressurized perfusion system (ALA Scientific Instruments).

**Stimulation protocols and data analysis.** The holding potential (V₀) was −80 mV unless otherwise stated. Voltage-dependent inhibition of peak inward Na⁺ current (Iₙa) by TZDs was analyzed using a 10-ms test pulse to 0 mV preceded by a 300-ms prepulse alternating to either −130 mV (Vₚ) or the voltage of half-maximal inactivation (V₁/₂ = −68 ± 5 mV), applied every 5 s (Lundbeck et al., 2004). V₁/₂ was determined for each cell using the two-pulse protocol described below.

For examining Na⁺ channel activation, currents were evoked by a series of 10-ms pulses ranging from −60 to +70 mV in 10-mV steps every 5 s. The conductance (Gₙa) was calculated as Gₙa = Iₙa / (Vₚ − Eₙa), where Iₙa is the peak inward current, Vₚ is the amplitude of the voltage step, and Eₙa is the reversal potential (about +65 mV), as estimated using the Nernst equation and the internal and external Na⁺ concentrations of 10 and 150 mM, respectively; the recorded Eₙa varied between 65 and 68 mV and did not change with TZD application (not depicted). The normalized conductance (G / Gₘₙₐₓ, where Gₘₙₐₓ is the maximal conductance) was plotted versus Vₚ and fitted with a Boltzmann function:

\[
G / Gₘₙₐₓ = 1 / [1 + \exp \left( - e / zₙ \cdot (Vₚ - V₁/₂) / kₙT \right) ],
\]

Sodium channel current measurements

**Cell culture.** The ND7/23 rat dorsal root ganglion/mouse neuroblastoma fusion cell line (Sigma-Aldrich) was cultured in Dulbecco’s modified Eagle’s medium (Invitrogen) supplemented with 10% (vol/vol) fetal bovine serum (Invitrogen), 2 mM t-glutamine, 100 U/ml penicillin, and 100 µg/ml streptomycin (Invitrogen) at 37°C under 95% air/5% CO₂. Cells were grown on 12-mm glass coverslips in 35-mm polystyrene culture dishes and used within 48–72 h of plating.

**Electrophysiology.** Endogenous TTX-sensitive Na⁺ currents (ND7/23 cells express a combination of Na⁺ subtypes 1.1, 1.2, 1.6, and 1.7, as shown by Western blotting; not depicted) were recorded using the whole cell clamp configuration (Hamill et al., 1981). Coverslips containing ND7/23 cells were transferred into a small-volume open bath chamber (Warner Instruments) and continuously perfused at ~2 ml/min with a solution containing (in mM): 130 NaCl, 10 HEPES, 3.25 KCl, 2 MgCl₂, 2 CaCl₂, 20 TEACl, and 5 mg/glucose, adjusted to pH 7.4 (with NaOH), and 310 mOsm/kg H₂O (with sucrose).
where $V_a$ is the potential for half-maximal activation, $e$ is the elementary charge, and $z_a$ is the apparent gating valence.

Steady-state fast inactivation, or “Na+ channel availability,” $h_{\text{in}}$, in Hodgkin and Huxley (1952), was measured using a double-pulse protocol with a 300-ms prepulse ranging from $-130$ to $-10$ mV in 10-mV steps, followed by a test pulse to 0 mV. Peak currents during the test pulse were normalized to the maximal current ($I_{\text{max}}$, where $I_{\text{max}}$ is the maximal current that is elicited at the test potential), plotted versus the prepulse potential ($V_{\text{m}}$), and fitted with a Boltzmann function:

$$I / I_{\text{max}} = 1 / \left(1 + \exp \left( - e \cdot z_{1/2} \cdot (V_{\text{m}} - V_{1/2}) / k_B T \right) \right), \quad (9)$$

where $z_{1/2}$ and $V_{1/2}$ denote the apparent gating valence and potential for half-maximal inactivation.

Statistical significance was assessed by two-tailed paired Student’s $t$ test. $P < 0.05$ was considered statistically significant. Programs used for data acquisition and analysis were pClamp 10 (Molecular Devices), Excel (Microsoft), and Prism 5.0 (GraphPad Software Inc.). Values are reported as mean ± SD unless otherwise stated.

**Online supplemental material**

Fig. S1 shows TZD’s effects on gA single-channel currents. Fig. S2 shows ciglitazone’s effects on gA single-channel currents at pH 6, 7, and 8. Fig. S3 shows pioglitazone’s effects on gA function at pH 6. Fig. S4 shows TZD effects on gA channel lifetimes. Fig. S5 shows changes in gA (13) lifetimes relative to changes in AgA(15) lifetimes in the presence of TZDs. Fig. S6 shows relative lifetimes of gA (15) and gA(17) in DC$_{20}$:1PC bilayers as function of [ciglitazone]. Fig. S7 compares the effects of troglitazone and ciglitazone on gA activity in the presence and absence of cholesterol in DC$_{18}$:1PC bilayers. Fig. S8 shows fluorescence quenching traces from stopped-flow experiments with ciglitazone and troglitazone. Fig. S9 shows dilution enthalpies of lipid in TZD-free buffer solution. Fig. S10 shows timed control experiments for the Na$_V$ inactivation experiments.

**RESULTS**

**Gramicidin experiments**

TZDs alter gA channel function. The TZD effects on gA channel function were examined by comparing the gA single-channel properties before and after the addition of each TZD. The left-handed 13–amino acid gA$^{-}$ (13) and the right-handed 15–amino acid AgA(15) analogues form channels with characteristic current transition amplitudes, marked in Fig. 3A by red and blue lines for gA$^{-}$ (13) and AgA(15), respectively. (Because the two analogues form channels having opposite handedness, they do not form heterodimers.) Fig. 3 (A–D) shows single-channel activity before and after the addition of each TZD.

**Changes in gA single-channel properties.** The changes in gA channel activity reflect changes in the energetics of

$$I_{\text{I}_{\text{max}}} = \frac{1}{1 + \exp \left( - e \cdot z_{1/2} \cdot (V_{\text{m}} - V_{1/2}) / k_B T \right) }, \quad (9)$$
The conductance changes caused by ciglitazone could reflect that ciglitazone is a weak acid (pK of ~6.4; Giaginis et al., 2007). Adsorption of the anionic form of ciglitazone at the bilayer/solution would increase the local [Na⁺], and thus the single-channel conductance (Apell et al., 1979). If so, the ciglitazone-induced conductance should be pH dependent, which it is; at pH 8, the conductance increase was greater than at pH 7, and at pH 6, there was no conductance increase (Fig. S2). These results suggest that the conductance changes occur because the anionic form of ciglitazone adsorbs at the bilayer–solution interface and effectively excludes that the conductance changes are a result of changes in the interfacial dipole potential. We also examined whether similar pH-dependent conductance changes occurred with pioglitazone. They did not (Fig. S3). We do not understand why only ciglitazone alters the single-channel conductance.

Troglitazone increased the lifetimes (τ) of both gA⁻ (13) and AgA(15) channels with a 50% increase at 1 µM (Figs. 4 C and 5 A). Rosiglitazone caused similar increases in τ, but at 30-fold higher concentrations (Figs. S4 B and 5 B). Pioglitazone did not alter τ at concentrations up to 10 µM, its solubility limit (Figs. S4 C and 5 C). Ciglitazone caused moderate increases in τ at concentrations up to 6 µM, where the effect appears to saturate (Figs. 4 D and 5 D). (The ciglitazone-induced changes in τ did not vary as a function of pH; not depicted.)

Similar to many other amphiphiles (Lundbæk et al., 2005), troglitazone, rosiglitazone, and ciglitazone caused larger relative increases in τ of gA⁻ (13) as compared with AgA(15) channels (Fig. S5, A, B, and D). We return to this below.

The TZDs also alter the channel appearance frequencies (f) (Fig. 3). The changes in f were evaluated in experiments in which the bilayer did not break during/after the addition of the TZD (Fig. 5, E–H), which limits our ability to explore changes caused by troglitazone and rosiglitazone above 1 and 30 µM, respectively, because bilayers break upon the addition of higher concentrations. 1 µM troglitazone (Fig. 5 E), 30 µM rosiglitazone (Fig. 5 F), and 10 µM pioglitazone (Fig. 5 G) increased f for gA⁻ (13) and AgA(15) channels, with the larger effect on the shorter gA⁻ (13) channels. 6 µM ciglitazone reduced f for gA⁻ (13) channels to ~50% of control with little effect on AgA(15) channels (Fig. 5 H). This effect is, at least in part, dependent on channel–bilayer hydrophobic mismatch, as ciglitazone reduced f for AgA⁻ (15) channels in DC203:PC/ n-decane bilayers (not depicted).

Troglitazone and rosiglitazone had larger effects on f (Fig. 5, E and F) than on τ (Fig. 5, A and B), reflecting the greater sensitivity of the gA dimerization rate constant, as compared with the dissociation rate constant, to changes in bilayer properties (Lundbæk et al., 2005).

The TZDs alter lipid bilayer properties. The results in Figs. 3–5 show that the TZDs alter gA channel function. The TZDs have quantitatively similar effects on left- and right-handed gA channel formation. To characterize these changes, we examined the TZDs’ effects on gA single-channel current transition amplitudes, lifetimes, and appearance frequencies. The current transition amplitude histograms (Fig. 4, A and B, and Fig. S1), show that TZDs—except for ciglitazone, which caused a modest increase (Fig. 4 B)—did not alter the conductances of gA⁻ (13) or AgA(15) channels (not depicted).

The TZDs increase the lifetimes (τ) of both gA⁻ (13) and AgA(15) channels with a 50% increase at 1 µM (Figs. 4 C and 5 A). Rosiglitazone caused similar increases in τ, but at 30-fold higher concentrations (Figs. S4 B and 5 B). Pioglitazone did not alter τ at concentrations up to 10 µM, its solubility limit (Figs. S4 C and 5 C). Ciglitazone caused moderate increases in τ at concentrations up to 6 µM, where the effect appears to saturate (Figs. 4 D and 5 D). (The ciglitazone-induced changes in τ did not vary as a function of pH; not depicted.)

Similar to many other amphiphiles (Lundbæk et al., 2005), troglitazone, rosiglitazone, and ciglitazone caused larger relative increases in τ of gA⁻ (13) as compared with AgA(15) channels (Fig. S5, A, B, and D). We return to this below.

The TZDs also alter the channel appearance frequencies (f) (Fig. 3). The changes in f were evaluated in experiments in which the bilayer did not break during/after the addition of the TZD (Fig. 5, E–H), which limits our ability to explore changes caused by troglitazone and rosiglitazone above 1 and 30 µM, respectively, because bilayers break upon the addition of higher concentrations. 1 µM troglitazone (Fig. 5 E), 30 µM rosiglitazone (Fig. 5 F), and 10 µM pioglitazone (Fig. 5 G) increased f for gA⁻ (13) and AgA(15) channels, with the larger effect on the shorter gA⁻ (13) channels. 6 µM ciglitazone reduced f for gA⁻ (13) channels to ~50% of control with little effect on AgA(15) channels (Fig. 5 H). This effect is, at least in part, dependent on channel–bilayer hydrophobic mismatch, as ciglitazone reduced f for AgA⁻ (15) channels in DC203:PC/n-decane bilayers (not depicted).

Troglitazone and rosiglitazone had larger effects on f (Fig. 5, E and F) than on τ (Fig. 5, A and B), reflecting the greater sensitivity of the gA dimerization rate constant, as compared with the dissociation rate constant, to changes in bilayer properties (Lundbæk et al., 2005).

The TZDs alter lipid bilayer properties. The results in Figs. 3–5 show that the TZDs alter gA channel function. The TZDs have quantitatively similar effects on left- and
right-handed gA channels (Fig. 5), and when plotting \( \ln(\tau/\tau_{\text{ctrl}}) \), where “ctrl” denotes results in the absence of amphiphile, for gA(13) channels versus \( \ln(\tau/\tau_{\text{ctrl}}) \) for AgA(15) channels (Fig. 6), the results for the TZDs and structurally unrelated compounds (Lundbæk et al., 2010b) are described by a shared linear relation with a slope of \( \approx 1.2 \). That is, the TZDs conform to the pattern observed with other bilayer-modifying amphiphiles, indicating that all of these compounds alter the lifetimes by a common mechanism.

This commonality shows that these compounds act through a common mechanism and excludes that they alter \( \tau \) through direct interactions with the bilayer-spanning \( \beta_{6.3} \)-helical dimers. Because amphiphiles alter lipid bilayer properties, including their elastic moduli (e.g., Evans et al., 1995; Zhelev, 1998; Ly and Longo, 2004; Zhou and Raphael, 2005), the most likely common mechanism is that the TZD, like other amphiphiles, alter gA channel lifetimes by altering lipid bilayer properties.

The situation is more complicated, however. Although the ciglitazone-induced changes in \( \tau \) are consistent with bilayer-mediated mechanism (Fig. 6), no change in \( f \) of AgA(15) channels and a decrease in \( f \) for gA(13) channels indicate that this compound has additional effects. The decreased appearance frequency (for the gA(13) channels) could reflect a shift in the equilibrium between conducting single-stranded and nonconducting double-stranded dimers (Sychev et al., 1993; Greathouse et al., 1994; Galbraith and Wallace, 1998), or a shift between different monomeric conformers. We explored this using size-exclusion chromatography (SEC) and found no effect on the distribution between single-stranded and double-stranded conformers (Kapoor, R., personal communication). We conclude that ciglitazone does not have specific interactions with the bilayer-spanning single-stranded \( \beta_{5.3} \)-helical gA dimers. Pioglitazone did not alter \( \tau \) at the concentrations tested (Fig. 5 C), most likely reflecting its limited solubility and rather low logP, and consequently low membrane concentration. Yet, pioglitazone increases \( f \) with similar

---

Figure 5. TZD-induced changes in single-channel lifetime and appearance frequency. Relative changes in gA(13) (red squares) and AgA(15) (blue circles) channel lifetimes as a function of [TZD], normalized to the lifetimes before TZD addition for: (A) troglitazone (TRO), (B) rosiglitazone (ROS), (C) pioglitazone (PIO), and (D) ciglitazone (CIG; \( n = 4-7 \)). The appearance frequency after is normalized to the appearance frequency before the addition of the TZD: (E) 1 µM troglitazone (TRO), (F) 30 µM rosiglitazone (ROS), (G) pioglitazone (PIO), and (H) ciglitazone (CIG; \( n = 2-4 \)).

Figure 6. Changes in gA(13) channel lifetimes (\( \tau_{13} \)) as a function of the corresponding changes in AgA(15) channel lifetimes (\( \tau_{15} \)). Gray data are from Lundbæk et al. (2010b). The colored results are from this study; each point represents the average value from two to seven experiments. Color code: olive, troglitazone (TRO); pink, rosiglitazone (ROS); orange, ciglitazone (CIG); gray, pioglitazone (PIO). Linear fit (solid line) to the data points has a slope of 1.24 (\( r = 0.997 \)).
effects on right- and left-handed channels (Fig. 5 G). We do not understand why, but note that pioglitazone is completely inert in cholesterol-containing bilayers (see below), effectively excluding specific pioglitazone–gA interactions.

The TZDs do not alter bilayer thickness. The TZD-induced changes in gA channel function could result from changes in bilayer thickness. Bilayer thinning will result in capacitance increase $C_m = \varepsilon \varepsilon_0 / d_0$, where $C_m$ is the specific capacitance of the bilayer, $\varepsilon_0$ is the permittivity of free space, $\varepsilon$ is the relative dielectric constant, and $d_0$ is the bilayer hydrophobic thickness. We determined the TZDs’ effects on $C_m$ of DC$_{18:1}$PC bilayers. Troglitazone (mean ± SD: control, 4.8 ± 0.3 nF/mm$^2$; 10 µM troglitazone, 4.9 ± 0.2 nF/mm$^2$), rosiglitazone (control, 4.8 ± 0.2 nF/mm$^2$; 100 µM rosiglitazone, 4.7 ± 0.3 nF/mm$^2$), and pioglitazone (control, 4.9 ± 0.1 nF/mm$^2$; 10 µM pioglitazone, 4.9 ± 0.1 nF/mm$^2$) did not increase $C_m$, demonstrating that the increases in $\tau$ and $f$ do not result from bilayer thinning. 6 µM cigitazone increased $C_m \sim 16\%$ (C$_m$ ± SD: control, 4.9 ± 0.2 nF/mm$^2$; 6 µM cigitazone, 5.7 ± 0.2 nF/mm$^2$).

The modest cigitazone-induced increase in $\tau$ is not consistent with the bilayer thinning predicted from the capacitance increase. Rather, cigitazone may act like a hydrophobic anion and increase the membrane capacitance by intramembrane charge transfer (Fernández et al., 1983). Indeed, cigitazone increases the bilayer conductance. 10 µM cigitazone increases the steady-state conductance from $10^{-8}$ S/cm$^2$ to $4 \times 10^{-8}$ S/cm$^2$, consistent with an aqueous diffusion-limited current (Le Blanc, 1969). This effect seems to be specific for cigitazone; 6 µM troglitazone had no effect on the bilayer conductance.

The TZDs alter the energetics of gA dimerization and lipid bilayer elasticity. To minimize the exposure of hydrophobic residues to water, gA channels and their host bilayer are coupled though hydrophobic interactions, and the formation of gA channels of hydrophobic length ($l$) in a bilayer of hydrophobic thickness ($d_0$) causes a local change in bilayer thickness, a thinning because $l$ is less than $d_0$ (Fig. 2, C and D). Changes in the energetics of the associated bilayer deformation (Huang, 1986; Helfrich and Jakobsson, 1990; Nielsen et al., 1998; Nielsen and Andersen, 2000; Partenskii and Jordan, 2002) will alter the kinetics and energetics of gA channel formation (Lundbæk et al., 2010a).

From the changes in $f(= k_f [\text{I}]^2)$ and $\tau (= 1/ k_\tau)$, one can calculate the changes in the time-averaged channel density, $K_0$ (see Materials and methods). Table II summarizes the TZD-induced changes in $f\tau$ and $\Delta G_{\text{M-D}}$ for troglitazone, rosiglitazone, pioglitazone, and cigitazone. In the case of troglitazone and rosiglitazone, the TZDs appear to act through a bilayer-mediated mechanism (meaning that $\Delta G_{\text{prot-D}} = 0$) and $\Delta G_{\text{M-D}} = \Delta G_{\text{tot-M-D}}$.

In response to the bilayer deformation and associated $\Delta G_{\text{M-D}}$, the bilayer exerts a disjoining force ($F_{\text{dis}}$) on the channels. $F_{\text{dis}}$ varies as a function of the hydrophobic mismatch ($d_0 - \delta$), the elastic coefficients $H_B$ and $H_X$, and the intrinsic monolayer curvature $\gamma_0$ (see Eq. A5):

$$F_{\text{dis}} = 2 \cdot H_B \cdot (d_0 - \delta) - H_X \cdot \gamma_0.$$

The relative increases in $\tau$ for the gA$^-$ (13) channels were larger than for the AgA (15) channels (Figs. S5 A, B, and D, and 6), meaning that the hydrophobic mismatch-dependent term in Eq. 10 contributes to the changes in $F_{\text{dis}}$ (and $\Delta G_{\text{M-D}}$). Changes in $H_B$ ($l - d_0$) could be a result of changes in $H_B$ or $d_0$ (the gA channel structure, and thus $l$, is insensitive to changes in bilayer thickness; Wallace et al., 1981; Katsaras et al., 1992). The changes in $H_B$ can be estimated by comparing the relative change in the lifetimes of the longer and shorter channels (Lundbæk et al., 2010a):

$$\frac{\tau_{\text{M-D}}}{\tau_{\text{M-D}}} = \exp \left( \frac{2 \cdot \delta \cdot (H_B^{\text{TZD}} - H_B^{\text{M-D}}) \cdot (l_0 - l_1)}{h_0 T} \right),$$

where the subscripts 13 and 15 denote the two channel types. Using Eq. 11, we find that 6 µM troglitazone and 200 µM rosiglitazone decrease $H_B$ by $\sim 4$ kJ/(mole-nm$^2$) or $\sim 1.6$ $h_0 T$/nm$^2$, 1 µM troglitazone and 30 µM rosiglitazone decrease $H_B$ by $\sim 1.5$ kJ/(mole-nm$^2$) or $\sim 0.6$ $h_0 T$/nm$^2$. These changes in bilayer elasticity, although small compared with $H_B$ for DC$_{18:1}$PC/decane bilayers (56 kJ/(mole-nm$^2$) or 22.6 $h_0 T$/nm$^2$; Lundbæk et al., 2010a), are sufficient to account for the changes in bilayer deformation energy (see Discussion). (Similar estimates were not possible for pioglitazone and cigitazone because the lifetime changes were small, and the estimates were susceptible to even minor experimental noise.

| TZD          | $\Delta G_{\text{M-D}}$ (kJ/mole) | SD  | $\Delta G_{\text{tot-M-D}}$ (kJ/mole) | SD  |
|--------------|-----------------------------------|-----|--------------------------------------|-----|
| 1 µM troglitazone | -5.0                              | 0.60| -4.0                                 | 0.8 |
| 30 µM rosiglitazone | -5.0                              | 0.2 | -4.0                                 | 0.9 |
| 10 µM pioglitazone | -4.6                              | 1.2 | -4.2                                 | 1.3 |
| 6 µM cigitazone   | 1.7                               | 1.7 | -0.6                                 | 2.4 |

Results in kJ/mole, $n = 2–4$.
The ciglitazone-induced changes in $\tau$, however, are a result of changes in bilayer elasticity, as evident from the larger changes in $\tau$ of the gA$^-$ (13) channels, relative to the AgA(15) channels [Figs. 5 D, S5 D, and 6], and from the larger changes in $\tau$ of the AgA(15) channels in the thicker DC$_{20:1}$PC/ $n$-decane bilayers [Fig. S6], as compared with the DC$_{18:1}$PC/ $n$-decane bilayers [Fig. 5 D].)

**Effects of cholesterol.** We tested the most and least potent bilayer-modifying TZDs (troglitazone and pioglitazone) in cholesterol-containing bilayers. Cholesterol increases the bilayer elastic moduli (Evans and Needham, 1987; Evans and Rawicz, 1990; Needham and Nunn, 1990), meaning that the bilayers are more difficult to deform (Evans and Needham, 1987; Lundbæk et al., 1996).

Similarly to what was found with polyunsaturated fatty acids (Bruno et al., 2007), troglitazone has greater effects on gA lifetime (Fig. S8 A) and appearance frequency (Fig. S8 B) in cholesterol-containing bilayers. Pioglitazone, which had no effect on $\tau$ in cholesterol-free bilayers, changed neither $\tau$ (Fig. S7 A), $f$ (Fig. S7 B), nor $\Delta G_{\text{bil}}^{\text{MD}}$ (Fig. S7 C).

**TZD effects in hydrocarbon-free bilayers.** Planar bilayers used in the electrophysiological experiments contain decane. We also did experiments in hydrocarbon-free lipid vesicles, using a fluorescence-based assay for gA channel activity (Ingólfsson and Andersen, 2010). To monitor gA channel activity, ANTS-loaded large unilamellar vesicles are mixed with Tl$^+$, and the time course of fluorescence quenching is recorded (Fig. S8). The resulting quenching rate provides a measure of the time-averaged number of channels in the vesicles. Except for ciglitazone, the TZDs increased the quenching rates, with troglitazone being the most potent and pioglitazone the least (Fig. 7). Ciglitazone reduced the quenching rate, indicating that the (hydrophobic mismatch–dependent) reduction in channel appearance rate (Fig. 5 H) dominates over the increase in channel...
TZD partitioning into lipid bilayers. Hydrophobicity, as measured by octanol–water partitioning (logP; partitioning of only a single, usually the neutral, species; or logD<sub>7.4</sub>; distribution of all species present at pH 7.4), varies among the TZDs, with troglitazone and ciglitazone being the most hydrophobic, followed by pioglitazone and rosiglitazone (legend to Fig. 1). LogP (or logD) thus provides a good estimate for the partition coefficient of neutral, but not charged, solutes into lipid bilayers (Escher and Schwarzenbach, 1996). For the weakly acidic TZDs, pK<sub>a</sub> values of ~6.4 (Giaginis et al., 2007), the different electrostatic properties of the bilayer interface and the octanol–water phase may cause clogP (and logD<sub>7.4</sub>) to be poor predictors of TZD partitioning into bilayers. (pK<sub>a</sub> of the adsorbed TZDs is likely to be higher than the bulk pK<sub>a</sub> [cf. Peitzsch and McLaughlin, 1993], and it is unclear what fraction of the TZDs at the bilayer–solution interface is charged.) We therefore examined the interactions of TZDs with lipid bilayers using isothermal titration calorimetry (Heerklotz and Seelig, 2000).

Only rosiglitazone and troglitazone produced sufficient heats of partitioning to determine K<sub>W→L</sub><sup>N</sup>. Fig. 8 A (left) shows the titration of 200 µM rosiglitazone with 10-mM lipid vesicles (the lipid vesicle dilution enthalpy is negligible [Fig. S9] and is not considered in the data analysis).

Plotting the enthalpy per injection versus the injection number (Fig. 8 A, right) and fitting Eq. 7 to the results allows for determining K<sub>W→L</sub><sup>N</sup> (Fig. 8 B) and ΔH<sub>W→L</sub><sup>N</sup>, ΔG<sub>η</sub><sup>W→L</sup>, and T·ΔS<sub>η</sub><sup>W→L</sup> (Fig. 8 C). Log K<sub>W→L</sub><sup>N</sup> for both rosiglitazone (3.2) and troglitazone (4.5) were higher than the corresponding LogD<sub>7.4</sub> (legend to Fig. 1). The thermodynamic profile for the partitioning of troglitazone differed from that for rosiglitazone, with entropies dominating the former and enthalpy the latter, which could reflect different locations within the bilayer–solution interface.

TZDs effects on Na<sup>+</sup> on cell membranes

Voltage-dependent inhibition of Na<sup>+</sup> currents (I<sub>Na</sub>). As noted above (Table I), the TZDs modulate a variety of membrane proteins. We explored this question further using endogenous TTX-sensitive sodium currents in ND7/23 cells. We have previously found that amphiphiles that alter gA channel function (increase f and τ) also alter the function of voltage-dependent calcium and sodium channels (Na<sub>v</sub>) (Lundbæk et al., 1996, 2004, 2005). We therefore explored whether the TZDs also alter Na<sub>v</sub> function, and we compare their relative potencies on Na<sub>v</sub> and on gA channels as probes of changes in bilayer properties.

The TZDs produce a prepulse-dependent inhibition of peak I<sub>Na</sub> (Fig. 9 A). This was examined further using an alternating pulse protocol (Lundbæk et al., 2004). See the bottom of Fig. 9, with conditioning prepulses to either −130 mV (V<sub>0</sub>) or to a voltage at which about half the channels are in the fast-inactivated state (V<sub>1/2</sub> = −68 ± 2; see Fig. 9 B). After ~5 min of stable baseline recordings using this protocol, the TZDs were applied. The peak I<sub>Na</sub> during the test pulse was strongly reduced by 6 µM troglitazone (Tables III and S2), and the inhibition was stronger after a prepulse potential to V<sub>1/2</sub> than to V<sub>0</sub> (Fig. 9).

The inhibition was fully reversible when tested from V<sub>0</sub>, but only partially so when tested from V<sub>1/2</sub> (Tables III and S2). Similar complete and partial reversibility to the peak I<sub>Na</sub> in control. Troglitazone inhibits peak I<sub>Na</sub>, and the inhibition is larger after a prepulse to V<sub>1/2</sub>. The inhibition was fully reversible after washout (2 min) when tested after a prepulse to V<sub>0</sub> mV; the inhibition was only partially reversible when tested after a prepulse to V<sub>1/2</sub> (n = 4).
after prepulses to $V_0$ or $V_{1/2}$, respectively, was observed with rosiglitazone. In contrast, the $I_{Na}$ inhibition by ciglitazone (at 6 µM) did not reverse for either conditioning pulse after washout times that were effective for troglitazone and rosiglitazone (2 min). Pioglitazone caused minimal current inhibition (at 10 µM). Fig. 10 compares inhibition of peak $I_{Na}$ at the highest concentrations tested, with 6 µM troglitazone being the strongest and 10 µM pioglitazone being the weakest inhibitor.

As in the bilayer experiments, ciglitazone increased the capacitance in the whole cell experiments (6 µM ciglitazone increased the capacitance ~15%, which was partially reversible after washout; not depicted); the other TZDs had no discernible effect. The ciglitazone-induced capacitance increase most likely reflects intramembrane transfer, as has been observed with other hydrophobic anions (Fernández et al., 1983).

**Effects of TZDs on $Na^+$ inactivation.** The steady-state inactivation ($h_\infty$ in the Hodgkin and Huxley, 1952, model) curve was determined using a double-pulse protocol. All the TZDs produced a hyperpolarizing shift in $V_{1/2}$ (Fig. 10 and Tables III and S3). The largest shift was seen with 6 µM troglitazone (~13.2 ± 4.1 mV, $n = 6$, and $P < 0.001$ vs. control), followed by 200 µM rosiglitazone (~5.4 ± 1.5 mV, $n = 3$, and $P < 0.05$), 6 µM ciglitazone (~3.0 ± 1.9 mV, $n = 4$, and $P < 0.05$), and 10 µM pioglitazone (~2.3 ± 0.4 mV, $n = 4$, and $P < 0.01$). Timed control experiment, done with the control buffer solution, showed no shift in $V_{1/2}$ during perfusion of the drug-free “sham drug” solution and subsequent “sham wash” (Table III and Fig. S10).

To determine whether the TZD-induced changes in $Na_V$ function could be related to the TZD-induced changes in gA channel function, we compared changes in $V_{1/2}$ (Fig. 11 B) to relative changes in gramicidin lifetime (Fig. 11 A) for each compound, as plotted in Fig. 11 C. The divergent $V_{1/2}$-[TZD] relations (Fig. 11, A and B) can be superimposed when using the TZD-induced changes in $r$ as a measure for the TZD-induced changes in bilayer properties. The $V_{1/2}$-[amphiphile] relations observed previously in studies on capsaicin and various detergents (Lundbæk et al., 2005). The amphiphile-induced changes in $Na_V$ (and gA channel) function do not appear to result from direct channel–amphiphile interactions but from altered channel–bilayer interactions.

**DISCUSSION**

TZDs alter gramicidin channel function at concentrations where they alter the function of many membrane proteins, including $Na_V$. The changes in $Na_V$ function

| Experimental condition | Prepulse to $V_0$ | Prepulse to $V_{1/2}$ | $V_{1/2}$ of $Na_V$ inactivation |
|------------------------|------------------|-----------------------|----------------------------------|
|                        | norm $I_{Na}$    | SD                    | $V_{1/2}$ (mV)                  | SD                    | $n$ | $\Delta V_{1/2}$ | SD |
| Control                | 1.00             | #                     | 1.00                            | 1.00                  | 7   | 2.3             | 6  | 61 |
| 6 µM troglitazone      | 0.62             | 0.62                  | 0.12                            | 0.13                  | 7   | 0.8             | 4  | 41 |
| Wash                   | 0.97             | 0.97                  | 0.05                            | 0.08                  | 7   | 0.8             | 4  | 0.4 |
| Control                | 1.00             | #                     | 1.00                            | #                     | 3   | 0.8             | 4  | 0.4 |
| 200 µM rosiglitazone   | 0.84             | a                     | 0.04                            | 0.04                  | 3   | 0.8             | 4  | 0.4 |
| Wash                   | 0.97             | 0.97                  | 0.01                            | 0.03                  | 3   | 0.8             | 4  | 0.4 |
| Control                | 1.00             | #                     | 1.00                            | #                     | 4   | 0.8             | 4  | 0.4 |
| 10 µM pioglitazone     | 0.97             | 0.97                  | 0.02                            | 0.01                  | 4   | 0.8             | 4  | 0.4 |
| Wash                   | 1.01             | 1.01                  | 0.05                            | 0.11                  | 4   | 0.8             | 4  | 0.4 |
| Control                | 1.00             | #                     | 1.00                            | #                     | 7   | 0.8             | 4  | 0.4 |
| 6 µM ciglitazone       | 0.74             | 0.74                  | 0.03                            | 0.11                  | 7   | 0.8             | 4  | 0.4 |
| Wash                   | 0.77             | 0.77                  | 0.04                            | 0.16                  | 7   | 0.8             | 4  | 0.4 |
| Control                | #/a              | #/a                   | 1.00                            | 1.00                  | 7   | 0.8             | 4  | 0.4 |
| Sham drug              | n/a              | n/a                   | 0.02                            | 0.01                  | 4   | 0.8             | 4  | 0.4 |
| Sham wash              | n/a              | n/a                   | 0.04                            | 0.11                  | 7   | 0.8             | 4  | 0.4 |

The TZD effects on peak $I_{Na}$ after prepulses to ~150 mV ($V_0$) or to a voltage at which approximately half the channels are in the fast-inactivated state ($V_{1/2}$). The currents were measured after 1-min perfusion of the drug. Fractional peak $I_{Na}$ was normalized to the control value. Right column of the table shows the effects of TZDs on steady-state inactivation (or $Na^+$ channel availability $h_\infty$ in the Hodgkin and Huxley, 1952, model). $V_{1/2}$ values were determined in control after 1-min perfusion of the drug and after 2-min washout of the drug. All TZDs significantly shifted $V_{1/2}$ toward hyperpolarized potentials. Stimulation protocols as described in detail in Materials and methods and can also be seen in Fig. 10.

$^a$P < 0.001 versus control by paired two-tailed Student’s $t$ test.

$^b$P < 0.01 versus control by paired two-tailed Student’s $t$ test.

$^c$P < 0.05 versus control by paired two-tailed Student’s $t$ test.
correlate with the changes in gA channel function, following the pattern observed previously for other amphiphiles (Lundbæk et al., 2005; Fig. 11), suggesting that the TZDs (and the other amphiphiles) alter the function of both channels through a common mechanism. Given that the only common feature of gA and NaV channels is that they are embedded in lipid bilayers, the most likely common mechanism is that the TZDs adsorb to lipid bilayers to alter their properties. As we discuss below, the changes in gA and NaV channel function occur at TZD concentrations that are similar to (for ciglitazone, pioglitazone, and troglitazone) or somewhat higher than (rosiglitazone) the plasma concentrations in patients (or animals) treated with TZDs.

We first discuss the concentrations at which the TZDs alter lipid bilayer properties; TZDs bind to plasma proteins and partition between the electrolyte and bilayer, and the free concentrations will be less than the nominal concentrations. We next consider the changes in gA channel function, as reporters of changes in bilayer properties. We then consider the possible confounding effects of n-decane in the planar bilayer experiments. Next, we discuss the changes in NaV channel function and the relationship between the changes in NaV and gA channel function. Finally, we consider how changes in lipid bilayer properties may constitute a general mechanism for the off-target effects of hydrophobic/amphiphilic drugs, including the TZDs.

At what concentrations do the TZDs alter lipid bilayer properties?
The TZDs are hydrophobic, with octanol–water partition coefficients, expressed as clogP or logD7.4, between 2.8 and 2.6 (for rosiglitazone) and 5.7 and 4.6 (ciglitazone; legend to Fig. 1). Thus, they are likely to partition into bilayers and bind to proteins, and the free

![Figure 10. The effect of TZDs on NaV steady-state fast inactivation.](image)

6 µM troglitazone (TRO, olive traces and symbols; ΔV1/2 = −13.2 ± 4.1 mV, n = 6, and P < 0.001 vs. control by paired two-tailed Student’s t test), 200 µM rosiglitazone (ROS, pink traces and symbols; ΔV1/2 = −5.4 ± 1.5 mV, n = 3, and P < 0.05), 10 µM pioglitazone (PIO, gray traces and symbols; ΔV1/2 = −2.3 ± 0.4 mV, n = 4, and P < 0.05), and 6 µM ciglitazone (CIG, orange traces and symbols; ΔV1/2 = −3.0 ± 1.9 mV, n = 4, and P < 0.05).
drug concentration will be less than the nominal concentration (Søgaard et al., 2006; Bruno et al., 2007; Ingólfsson et al., 2007).

The TZDs are weak acids, and water–octanol partition coefficients thus may be poor predictors of TZD partitioning into bilayers (Escher and Schwarzenbach, 1996; Avdeef et al., 1998). We therefore measured their partition coefficients ($K_p$) into lipid bilayers using isothermal titration calorimetry. Troglitazone and rosiglitazone had sufficient partition enthalpy to allow for the determination of $K_p$. The measured log $K_p$s (Fig. 8) are close to, but higher than, log $D_{7.4}$. The relationship to $\log D_{7.4}$ is more complicated: for troglitazone, $\log D_{7.4} < \log K_p$; for rosiglitazone, $\log K_p > \log D_{7.4}$ (compare Fig. 8 and legend to Fig. 1). On balance, the results suggest that one can use log $D_{7.4}$ and $\log K_p$ to estimate the bilayer partition coefficients (see below). (The planar bilayer experiments were done using 1M NaCl, and the vesicle experiments were done using 140 mM NaNO$_3$; however, ionic strength effects on $pK_a$ are small [cf. Harned and Owen, 1943; Rossotti and Rossoti, 1961]. Similarly, ionic strength effects on partitioning will be small because we use zwitterionic DC$\text{18:1}_{\text{PC}}$ and rather low TZD concentrations; salting-in or -out effects likewise will be small [cf. Edsall and Wyman, 1958]. We do not consider these effects further.)

Knowing the partition coefficients, we can estimate the free drug concentrations (Bruno et al., 2007; Ingólfsson et al., 2007; see Appendix). At the concentrations listed, the mole fractions ($m_{TZD}$) are small (Table IV), at 0.03 or less. The different mole ratio of troglitazone and rosiglitazone needed to alter bilayer properties may reflect that they localize differently in the bilayer–solution interface (as suggested by the different enthalpic and entropic contributions to the free energy of portioning). There are 10 lipids in the first shell around a gA, so there will be less than one TZD in the first shell, unless the TZDs accumulate in the perturbed bilayer adjacent to the channel (Andersen et al., 1992; Bruno et al., 2007). This is unlikely, at least in the case of ciglitazone, because the conductance changes do not depend on bilayer thickness (Fig. S11), indicating that ciglitazone does not partition preferentially into, or out of, the perturbed bilayer region (see also, Bruno et al., 2007).

Although the $m_{TZD}$s are small, the volume-averaged TZD concentrations in the bilayer are high, ranging from 1 to 15 mM.

To compare with clinical concentrations, Table IV lists literature values for the total and free TZD concentrations in vivo and in vitro. For troglitazone and ciglitazone, the total and free plasma concentrations are similar to those in the bilayer experiments. For rosiglitazone, the concentrations in the bilayer experiments are higher than the plasma concentrations.

Changes in gA channel function and in bilayer properties
Gramicidin channels form by transbilayer dimerization of subunits in opposing bilayer leaflets (O’Connell et al., 1990), which make them suitable to probe for changes in bilayer properties (Lundbæk et al., 2005). gA channel function, specifically the channel appearance frequency and lifetime, depends on how easy it is to deform the bilayer when the channel forms. The less energy required for bilayer deformation, the more likely it is that monomer
encounters will result in successful dimerization, and the smaller will be the disjoining force acting on the bilayer-spanning dimer.

Many amphiphiles, including the TZDs, alter gA channel appearance frequencies and lifetimes (see Lundbæk et al., 2010a), meaning that they alter lipid bilayer properties when they adsorb at the bilayer–solution interface. The common relation between the relative increases in $\tau$ for the gA(13) and AgA(15) channels caused by troglitazone, rosiglitazone, ciglitazone, and other bilayer-modifying amphiphiles (Lundbæk et al., 2010b; Fig. 6) indicates that these compounds alter gA channel lifetimes by a common mechanism that does not involve specific binding.

Ciglitazone’s effects are more complex (Figs. 3 and 5). Yet, the ciglitazone-induced changes in $\tau$ follow a simple pattern (Figs. 5 D and 6). First, in DC<sub>20:1</sub>PC bilayers, ciglitazone causes a greater increase in $\tau$ for the shorter AgA<sup>+</sup>(15) compared with the longer gA(17) channels (Fig. S6). Second, the increase in $\tau$ of AgA<sup>+</sup>(15) channels in DC<sub>20:1</sub>PC/n-decane bilayers is greater than the increase in AgA<sup>+</sup>(15) channels in DC<sub>18:1</sub>PC/n-decane bilayers (Figs. 5 D and S6), meaning that the increase in $\tau$ depends on the channel–bilayer hydrophobic mismatch. Third, ciglitazone alters $\tau$ of both AgA<sup>+</sup>(15) and AgA<sup>+</sup>(15) channels (Figs. 5 D and S6). Ciglitazone’s effects on $\tau$ vary with hydrophobic mismatch, not the detailed channel structure, indicating that it alters $\tau$ through increases in bilayer elasticity.

Troglitazone, rosiglitazone, and pioglitazone increased $f$, ciglitazone decreased $f$. The changes in lifetimes and appearance frequencies caused by troglitazone and rosiglitazone follow the pattern observed for other amphiphiles (unpublished data), meaning that these molecules shift the monomer–dimer equilibrium toward the dimer and thus reduce $\Delta G_{\text{bil}}^{\text{m-d}}$ (Table II). Pioglitazone did not change $\tau$, indicating that it does not alter bilayer elasticity at attainable concentrations. It does, however, increase $f$ for both the left-handed gA<sup>+</sup>(13) and the right-handed gA channels, which could be because of a shift between $\beta^{3,3}$-helical and non-$\beta^{3,3}$-helical monomers (by a mechanism that does not involve direct gramicidin–pioglitazone interactions, as pioglitazone is completely inert in cholesterol-containing bilayers; Fig. S7). Ciglitazone also has complex effects. The decreases in $f$ (Figs. 3 and 5 G) indicate that it alters gA channel function by a mechanism not involving changes in bilayer elasticity. Ciglitazone does not appear to interact with the $\beta^{3,3}$-helical dimers (channels); however, nor does it alter the equilibrium between single-stranded and double-stranded dimers in SEC experiments (Kapoor, R., personal communication). SEC experiments, however, are done at high gA/lipid ratios (1:20–1:100; Bañó et al., 1992), where all gA is dimeric, and do not provide information about monomers. The decreases in $f$ are observed at gA/lipid mole ratios at $\tau$=1:10<sup>6</sup>, where gA is mostly monomeric (Durkin et al., 1990). Although bilayer-embedded gA monomers are $\beta^{3,3}$-helical at high gA/lipid ratios (He et al., 1994), maybe ciglitazone shifts the distribution among the monomers toward non-$\beta^{3,3}$-helical conformers at low gA/lipid ratios.

To check whether the changes in the gA monomer⇌dimer equilibrium could be solely the result of changes in bilayer elasticity, we compare two different approaches to estimate $\Delta G_{\text{bil}}^{\text{m-d}}$. Based on the changes in $\tau$ and using Eq. 11, 1 µM troglitazone and 30 µM rosiglitazone decrease $H_{b}$ by $\sim$1.5 kJ/(mol·nm<sup>2</sup>) or $\sim$0.6 kT/nm<sup>2</sup>. Although small in relation to $H_{b}$, 56 kJ/(mol·nm<sup>2</sup>) or 22 kT/nm<sup>2</sup> (Lundbæk et al., 2010a), these changes in $H_{b}$ are sufficient to account for the measured changes in $\Delta G_{\text{bil}}^{\text{m-d}}$. The hydrophobic mismatch-dependent contribution to $\Delta G_{\text{bil}}^{\text{m-d}}$ ($\Delta G_{\text{bil}}^{\text{m-d}}(H_{b} - H_{b,\text{run}}) \cdot (l - d_{0})^{3}$) then can be estimated from the changes in $H_{b}$, knowing that $d_{0}$ is unchanged (see Results) (Fig. 12). This estimate for $\Delta G_{\text{bil}}^{\text{m-d}}$ can be compared with changes in $\Delta G_{\text{bil}}^{\text{m-d}}$ estimated using the time-averaged channel concentrations and Eq. 4 (Table II).
For AgA(15) channels, $l = 2.2$ nm (Table S1) and $d_0 = 4.0$ nm (Lundbæk et al., 2010b), and the $(H_n - H_{B,rel})\cdot(l - d_0)^2$ contribution is estimated to be $-4$ to $-7$ (kJ/mol), comparable to the $-4$ (kJ/mol) calculated from changes in time-averaged dimer concentrations (Table II). For gA$^-$ (13) channels, $l = 1.9$ nm (Table S1), and the $(H_n - H_{B,rel})\cdot(l - d_0)^2$ contribution is estimated to be $-5$ to $-9$ (kJ/(mol·nm$^2$)), somewhat larger than the estimates in Table II. The effects of troglitazone and rosiglitazone can be accounted for by changes in bilayer elasticity.

Adding cholesterol to the bilayer-forming solution altered the TZD bilayer-modifying potency: troglitazone's was increased—both the lifetime and appearance rate changes were larger in the cholesterol-containing bilayers (Fig. S7); pioglitazone's was decreased—neither $\tau$ nor $f$ was altered, suggesting that the pioglitazone–induced increases in $f$ are not a result of specific interactions with the gramicidins. Changes in bulk membrane properties alter the TZDs' efficacy, although the direction of the changes in efficacy may vary.

The TZDs have similar effects in hydrocarbon-containing and hydrocarbon-free bilayers

TZDs alter lipid bilayer properties in both hydrocarbon-containing planar bilayers and hydrocarbon lipid vesicles (compare Figs. 5, 6, and 7). The effective concentration ranges and relative potencies were similar in planar bilayers (Figs. 5 and 6), decane-free large unilamellar vesicles (Fig. 7), and in biological membrane as reported by changes in Na$^+$ currents (Fig. S7); pioglitazone's was decreased—neither $\tau$ nor $f$ was altered, suggesting that the pioglitazone–induced increases in $f$ are not a result of specific interactions with the gramicidins. Changes in bulk membrane properties alter the TZDs' efficacy, although the direction of the changes in efficacy may vary.

This is not surprising. $n$-Decane–containing planar bilayers are softer than nominally hydrocarbon-free bilayers (Lundbæk and Andersen, 1999), but the ln($\tau$)–$d_0$ relations in planar bilayers are linear (Lundbæk and Andersen, 1999; Lundbæk et al., 2010a), meaning that $F_{ci}$ is a linear function of $d_0 - l$ (cf. Eq. A5). That is, the expression for $\Delta G_{\text{M-D}}$ includes a term that is quadratic in $d_0 - l$ (cf. Eq. A4). We further note that the lipid intrinsic curvature usually is determined in x-ray scattering experiments on lipid–hydrocarbon systems (Turner and Gruner, 1992; Chen and Rand, 1998), and that the hydrocarbons have relatively little effect on the measured values (Chen and Rand, 1998). ($n$-Decane–containing planar bilayers are under tension [e.g., Elliott et al., 1983], whereas the lipid vesicles used in the fluorescence experiments may not be. gA channel lifetimes, however, are little affected by changes in membrane tension per se [Huang, 1986; Goulian et al., 1998], although channel function may be altered by tension-dependent changes in bilayer thickness [Goulian et al., 1998].)

Changes in Na$^+$ channel function

Previous studies have shown that troglitazone is a more potent modifier of ion channel function than the other TZDs (Table I). Few studies, however, have compared different TZDs’ effects on the same system. We therefore compared the effects of the four TZDs on the activity of endogenous Na$^+$ channels in a mammalian cell line. The TZDs inhibit peak currents and shift the $V_{1/2}$ for inactivation in the hyperpolarizing direction. Timed control experiments using a similar perfusion and pulse protocol as was used with the TZDs cause minimal changes in $V_{1/2}$ (Table III and Fig. S10). Except for ciglitazone, the inhibition is reversible when the test currents are measured after a prepulse to $-130$ mV, and we cannot exclude that ciglitazone interacts directly with Na$^+$, in addition to altering bilayer properties. When the currents are measured after a prepulse to $V_{1/2}$, the inhibition is not fully reversible, presumably reflecting that the shift in $V_{1/2}$ is not fully reversible. Maybe the TZDs accelerate the hyperpolarizing shift in $V_{1/2}$ that occurs in whole cell voltage-clamp studies (e.g., Fernandez et al., 1984; Wendt et al., 1992). In any case, the TZDs shift the equilibrium distribution between noninactivated (closed or open) and inactivated states toward the inactivated state(s). (The TZDs also alter Na$^+$ activation [Table S4] as well as the time course of inactivation and recovery from inactivation. These changes will be the focus of a forthcoming article [unpublished data].)

Because of redistribution between the aqueous solution and the membrane and other hydrophobic compartments, the free aqueous [TZD] may differ between the bilayer system and the whole cell voltage-clamp system (Søgaard et al., 2006; Bruno et al., 2007; Ingólfsson et al., 2007; Gingrich et al., 2009). Yet, troglitazone and rosiglitazone alter Na$^+$ function (Fig. 11 B) at the same nominal concentrations and with the same order of potency as gA function (Fig. 11 A). When plotting the hyperpolarizing shift of $V_{1/2}$ versus the change in gA lifetime (Fig. 11 C), the relationship between the changes

Figure 12. The troglitazone- (TRO, olive bars) or rosiglitazone- (ROS, pink bars) induced changes in the bilayer deformation energy, as determined from the changes in $H_n$ (the hydrophobic mismatch–dependent term in Eq. A4). 1 µM troglitazone and 30 µM rosiglitazone ($n = 4–6$).
in Na\textsubscript{v} function and gA channel lifetime is remarkably similar—and not just among the TZDs but also among other bilayer-modifying compounds. This commonality suggests that these structurally diverse compounds alter both Na\textsubscript{v} and gA channel function through a common mechanism that involves changes in bilayer properties. This does not exclude more direct drug channel interactions, for example, at the channel–bilayer boundary (Andersen, 2008), that also may alter the energetic coupling between lipid bilayers and their embedded proteins. Detergents (Deisenhofer et al., 1995) and small amphiphiles (Nury et al., 2011), for example, can bind at the protein–bilayer interface, which means that they can alter protein function by altering the energetic coupling between the bilayer and its embedded ion channels. We conclude that the TZDs alter the equilibrium between noninactivated (closed or open) and inactivated Na\textsubscript{v} states by changing the bilayer elasticity (the bilayer deformation energy associated with the transition into the inactivated state). That is, the bilayer becomes an allosteric regulator of Na\textsubscript{v} function.

The lipid bilayer as a mediator of off-target drug effects: implications for drug development

Our results suggest that gA channels can be used to "predict" whether amphipathic/hydrophobic molecules are likely to perturb membrane protein function, and at what concentrations. The correlation between the changes in gA channel lifetimes and the shift in the \(V_{1/2}\) for Na\textsubscript{v} inactivation is remarkable considering that Na\textsubscript{v} channels are structurally and functionally very different from gA channels. This ability to predict changes in Na\textsubscript{v} channel function from changes in gA function suggests that ion channel (membrane protein) function is regulated by changes in bilayer properties, including adaptations in the lipids in immediate contact with the protein, strengthening the conclusions of previous studies (Lundbæk et al., 2005; Artigas et al., 2006; Søgaard et al., 2006).

The TZDs were discovered in a search for hypolipidemic clofibrate-type compounds (Hulin et al., 1996). Ciglitazone was the first TZD to be explored for clinical use; it was discontinued during Phase II trials (Scheen, 2001). It was followed by troglitazone, rosiglitazone, and pioglitazone, the three TZDs actually marketed as insulin sensitizers. Roglitazone was later withdrawn (Scheen, 2001), and rosiglitazone is restricted in the United States (Food and Drug Administration, 2010) and suspended in Europe (European Medicines Agency, 2011). The TZDs modify lipid bilayer properties with the order of potency, troglitazone > ciglitazone > rosiglitazone ≥ pioglitazone, which differs from their hydrophobicity (legend to Fig. 1), ciglitazone > troglitazone > pioglitazone > rosiglitazone, and their affinity for PPAR\textgamma (Table I). Ciglitazone and troglitazone are the most potent gA channel and Na\textsubscript{v} modifiers—and the most hydrophobic. The concentrations where troglitazone alters gA channel function are similar to the clinical plasma concentrations (Table IV). Troglitazone alters the function of many membrane proteins at concentrations where it alters bilayer properties (Table I), and some of its PPAR\textgamma-independent effects, such as vasorelaxation and acute glucose uptake (Fujwara et al., 1988; Nakamura et al., 1998; Fujwara and Horikoshi, 2000), could arise from its bilayer-modifying effects. Troglitazone’s bilayer-modifying properties also could account for its hepatotoxicity that may be a result of inhibition of hepatic bile acid transport (Snow and Moseley, 2007).

Rosiglitazone and pioglitazone, which have the least clogP and logD\textsubscript{7.4}, are the least bilayer modifying. Pioglitazone, the least potent bilayer modifier, has less cardiovascular side effects than rosiglitazone (Graham et al., 2010; Juurlink, 2010; Nissen and Wolski, 2010). Rosiglitazone’s clinical side effects, however, occur at concentrations where it has minimal bilayer-modifying effects (compare Table IV). The bilayer-modifying potency of TZDs, as expressed in changes in gA channel function, can be used to predict the likelihood and severity of side effects at the TZDs’ plasma concentrations during treatment. But these drugs do, of course, also cause side effects through mechanisms unrelated to their bilayer effects.

The TZDs are part of a growing library of molecules that alter gA channel function (e.g., Lundbæk et al., 2010a). It has long been known that hydrophobic drugs have “membrane effects” (e.g., Seeman, 1972), and the bilayer-perturbing effects of hydrophobic drugs have been characterized using a variety of physicochemical probes (Seddon et al., 2009). It has proven difficult, however, to relate changes in bilayer properties, as deduced from changes in some physicochemical probes, to changes in membrane protein function, and the changes in bilayer properties may not be causally related to the changes in protein function (Spector and Yorek, 1985). Many of these difficulties can be overcome using gA channels to “sense” aggregate changes in bilayer properties and report them as changes in bilayer deformation energy (or the disjoining force acting on the channels). This is important because bilayer-spanning membrane proteins are energetically coupled to their host bilayer through hydrophobic interactions, meaning that there will be a bilayer contribution to the energetics (and kinetics) of protein conformational changes that involve the protein–bilayer boundary, which provides for mechanistic insights into hydrophobic drugs’ “membrane effects.”

The ability of hydrophobic drugs to alter membrane protein function correlates with their ability to alter gA channel function (Fig. 11), making it possible to explore a drug candidate’s bilayer-perturbing potential early in product development (Leeson and Springthorpe, 2007; Lundbæk, 2008). It is not sufficient to focus just
on hydrophobicity ("lipophilicity" in the drug development literature), because hydrophobicity per se may not predict a compound's bilayer-modifying potential, as evident in our results and from a previous study showing that oleic acid has a higher bilayer partition coefficient than docosahexaenoic acid, yet docosahexaenoic acid is the more potent bilayer modifier (Bruno et al., 2007). A drug must be sufficiently hydrophobic to reach its target (Lipinski et al., 2001), and too high hydrophobicity is likely to be problematic because the drug may partition strongly into lipid bilayers, but increased hydrophobicity cannot be equated with increased bilayer-modifying propensity. It is important to explicitly test whether a drug lead is a bilayer modifier using probes that sense relevant (for membrane proteins) changes in bilayer properties, such as the gA channels.

**APPENDIX**

**Energetics of lipid bilayer deformations**

The bilayer deformation energy ($\Delta G_{\text{def}}$) associated with a local bilayer thinning can be expressed as:

$$\Delta G_{\text{def}} = H_b \cdot (l - d_b)^2 + H_X \cdot (l - d_b) \cdot c_0 + H_c \cdot c_0^2,$$  \hspace{1cm} (A1)

where $H_b$, $H_X$, and $H_c$ are elastic coefficients that are functions of bilayer thickness, elastic moduli, and channel radius (and include contributions from the energetic cost of redistributing the different components in multi-component membranes, including redistribution of the decane in our planar bilayers), and $c_0$, the intrinsic monolayer curvature (Nielsen and Andersen, 2000).

Eq. A1 can be derived from the theory of elastic bilayer deformations (Nielsen and Andersen, 2000; cf. their Eq. 17). The biquadratic structure of Eq. A1 applies more generally, however (Andersen and Koepppe, 2007). Membrane protein function is regulated by experimental maneuvers that alter bilayer thickness and intrinsic lipid curvature (Andersen and Koepppe, 2007; Tables I and II), meaning that $\Delta G_{\text{def}}$ can be expressed as a function of $(l - d_b)$ and $c_0$, and maybe other terms. Using a Taylor expansion in $(l - d_b)$ and $c_0$, $\Delta G_{\text{def}}$ becomes:

$$\Delta G_{\text{def}}(l - d_b, c_0) = \Delta G_{\text{def}}^0(l - d_b, c_0) + \frac{\partial \Delta G_{\text{def}}^0}{\partial (l - d_b)} \cdot (l - d_b) + \frac{\partial \Delta G_{\text{def}}^0}{\partial c_0} \cdot c_0 + \frac{1}{2} \frac{\partial^2 \Delta G_{\text{def}}^0}{\partial (l - d_b)^2} \cdot (l - d_b)^2 + \frac{1}{2} \frac{\partial^2 \Delta G_{\text{def}}^0}{\partial (l - d_b) \partial c_0} \cdot (l - d_b) \cdot c_0 + \frac{1}{2} \frac{\partial^2 \Delta G_{\text{def}}^0}{\partial c_0^2} \cdot c_0^2 + ...,$$

(A2)

where the first-order terms will be zero when the bilayer can be approximated as an elastic body. (The deformation energy for small decreases in $(d_b - l)$ should equal that for small increases of equal magnitude, with a similar argument holding for $c_0$.) The biquadratic form of $\Delta G_{\text{def}}^0$ in Eq. A1 thus should be valid quite generally, assuming $\Delta G_{\text{def}}^0(0,0) = 0$, with (keeping the sign convention for the $H$ coefficients as in Lundbæk et al., 2010a, Eq. 2.6):

$$H_b = \frac{1}{2} \frac{\partial^2 \Delta G_{\text{def}}^0}{\partial (l - d_b)^2}, \quad H_X = \frac{\partial^2 \Delta G_{\text{def}}^0}{\partial (l - d_b) \partial c_0}, \quad \text{and} \quad H_c = -\frac{1}{2} \frac{\partial^2 \Delta G_{\text{def}}^0}{\partial c_0^2}. \hspace{1cm} (A3)$$

In multi-component bilayers, the derivatives in Eqs. A2 and A3 include contributions from the redistribution of bilayer components, whether it be lipids or hydrocarbon, meaning that Eq. A1 should also apply for hydrocarbon-containing lipid bilayers, which can be approximated as elastic bodies (White and Thompson, 1973; White, 1974; Evans and Simon, 1975; Requena et al., 1975).

In Eq. A1, the $-H_c \cdot c_0^2$ term is the deformation energy associated with embedding an inclusion of length $d_b$ (no hydrophobic mismatch) in a bilayer with intrinsic lipid curvature $c_0$, because of the need for the lipids to adapt to the channel. As noted by Fattal and Ben-Shaul (1993), this expression does not include the loss of conformational entropy of the acyl chains adjacent to the channel. Using Eqs. A2 and A3, the corresponding expression becomes $\Delta G_{\text{def}}^0(0,0) + 1/2 \left( \frac{\partial^2 \Delta G_{\text{def}}^0}{\partial c_0^2} \right) c_0^2$, where $\Delta G_{\text{def}}^0(0,0)$ is the energetic cost of embedding an inclusion of length $d_b$ in a bilayer with $c_0 = 0$, including the loss of conformational entropy. Whether using Eq. A1 or Eqs. A2 and A3, the $-H_c \cdot c_0^2$ term (in Eq. A1) or $\Delta G_{\text{def}}^0(0,0) + 1/2 \left( \frac{\partial^2 \Delta G_{\text{def}}^0}{\partial c_0^2} \right) c_0^2$ (in Eqs. A2 and A3) drops out in the expression for $\Delta G_{\text{bil}}^M$:

$$\Delta G_{\text{bil}}^M = H_b \cdot (l - d_b)^2 + H_X \cdot (l - d_b) \cdot c_0. \hspace{1cm} (A4)$$

The bilayer responds to the deformation by imposing a disjoining force ($F_{\text{dis}}$) on the channel (Andersen and Koepppe, 2007; Lundbæk et al., 2010a):

$$F_{\text{dis}} = \frac{\partial \Delta G_{\text{def}}}{\partial (d_b - l)} = 2 \cdot H_b \cdot (d_b - l) - H_X \cdot c_0, \hspace{1cm} (A5)$$

and changes in $F_{\text{dis}}$—as a result, for example, of the adsorption of TZDs at the bilayer-solution interface—will be observable as changes in $\tau$:

$$\tau_{\text{TZD}} = \exp \left[ \frac{(F_{\text{dis,TZD}} - F_{\text{dis,ctrl}})}{k_B T} \right], \hspace{1cm} (A6)$$

where $(d_b - l)$ is the distance the two monomers move apart to reach the transition state for channel dissociation.
framework provided by Eq. A3, making it possible to further explore the TZD-induced changes in bilayer properties, in particular, whether the changes in bilayer properties reflect changes in intrinsic curvature or elasticity. For example, if the TZDs cause larger relative changes in \( \tau \) for the shorter than for the longer channels, the changes in \( F_{\text{dis}} \) result, at least in part, from changes in the hydrophobic mismatch-dependent term in Eq. A5. Conversely, if the TZDs cause similar relative changes in \( \tau \) of the shorter and longer channels, the changes in \( F_{\text{dis}} \) result primarily from changes in the curvature-dependent term in Eq. A5.

**Free drug concentrations**

Let \( [\text{TZD}]_m \) denote the \([\text{TZD}]\) in each leaflet of the membrane (in moles/area) and \([\text{TZD}]_a\), the aqueous \([\text{TZD}]\):

\[
[TZD]_m = K_p \frac{d_0}{2} [TZD]_a. \tag{A7}
\]

Disregarding TZD adsorbed to the chamber, the contribution relation for the TZD becomes:

\[
[TZD]_{\text{nom}} = V_m [TZD]_m + V_q [TZD]_a + V_{\text{lip}} [TZD]_l, \tag{A8}
\]

where \([TZD]_{\text{nom}}\) is the nominal \([TZD]\) added to the aqueous solutions, \(V_q\) is the aqueous volume, and \(V_{\text{lip}}\) is the volume of the lipid-forming solution. Combining Eqs. A7 and A9:

\[
[TZD]_m = \frac{d_0}{2} [TZD]_{\text{nom}} = \frac{K_p [TZD]_{\text{nom}} V_m}{(V_m + K_p V_{\text{lip}})^2}. \tag{A9}
\]

In our case, \(V_m = 5\, \text{ml}, V_{\text{lip}} = 2\, \mu\text{l}, \text{and }d_0 = 4\, \text{nm} \) (Table IV). As we could not determine \(K_p\) for pioglitazone and ciglitazone, we approximate it using clogP.

We thank Dr. Vishwanath R. Lingappa for suggesting to us that we explore the bilayer-modifying potential of troglitazone and other TZDs. We thank Ruchi Kapoor for the SEC experiments, and Helgi I. Ingólfsson, Ruchi Kapoor, Kevin Lum, Roger E. Koepp II, and Jens A. Lundbek for discussions and comments on the manuscript. This work was supported by National Institutes of Health grants GM021342 and ARRA Supplement GM021342-35S1, GM058055, and RR015569.

Sidney A. Simon served as guest editor.

Submitted: 1 September 2010
Accepted: 1 July 2011

**REFERENCES**

Ahn, H.S., S.E. Kim, H.J. Jang, M.J. Kim, D.J. Rhie, S.H. Yoon, Y.H. Jo, M.S. Kim, K.W. Sung, S.Y. Kim, and S.J. Hahn. 2007. Open channel block of Kv1.3 by rosiglitazone and troglitazone: Kv1.3 as the pharmacological target for rosiglitazone. *Naunyn Schmiedebergs Arch. Pharmacol.* 374:305–309. doi:10.1007/s00210-006-0118-6

Aleo, M.D., C.M. Doshna, and K.A. Navetta. 2005. Ciglitazone-induced lenticular opacities in rats: in vivo and whole lens explant culture evaluation. *J. Pharmacol. Exp. Ther.* 312:1027–1033. doi:10.1124/jpet.104.076950

Avdeef, A., K.J. Box, J.E. Comer, C. Hibbert, and K.Y. Tan. 1998. pH-metric logP 10. Determination of liposomal membrane-water partition coefficients of ionizable drugs. *Pharm. Res.* 15:209–215. doi:10.1023/A:101954332221

Andersen, O.S. 1983. Ion movement through gramicidin A channels. Single-channel measurements at very high potentials. *Biophys. J.* 41:119–133. doi:10.1016/S0006-3495(83)84411-2

Andersen, O.S. 2005. Perspectives on how to drug an ion channel. *J. Gen. Physiol.* 131:395–397. doi:10.1085/jgp.200510112

Andersen, O.S., and R.E. Koepp II. 2007. Bilayer thickness and membrane protein function: an energetic perspective. *Annu. Rev. Biophys. Biomol. Struct.* 36:107–130. doi:10.1146/annurev.biophys.36.040306.132643

Andersen, O.S., D.B. Sawyer, and R.E. Koepp II. 1992. Modulation of channel function by the host bilayer. *In Biomembrane Structure and Function. K.R.K. Easwaran and B. Gaber, editors. Adenine Press, Schenectady, NY.* 227–244.

Andersen, O.S., M.J. Bruno, H. Sun, and R.E. Koepp II. 2007. Single-molecule methods for monitoring changes in bilayer elastic properties. *Methods Mol. Biol.* 400:543–570. doi:10.1007/978-1-59745-5190-3_7

APELL, H.J., E. Bamberg, and P. Läuger. 1979. Effects of surface charge on the conductance of the gramicidin channel. *Biochim. Biophys. Acta.* 552:369–378. doi:10.1016/0006-3788(79)90181-0

Artigas, P., S.J. Al'aref, E.A. Hobart, L.F. Díaz, M. Sakaguchi, S. Straw, and O.S. Andersen. 2006. 2,3-butanedione monoxime affects cystic fibrosis transmembrane conductance regulator channel function through phosphorylation-dependent and phosphorylation-independent mechanisms: the role of bilayer material properties. *Mol. Pharmacol.* 70:2015–2026. doi:10.1124/mol.106.026070

Ashrafuzzaman, M., M.A. Lampson, D.V. Greathouse, R.E. Koepp II, and O.S. Andersen. 2006. Manipulating lipid bilayer material properties using biologically active amphipathic molecules. *J. Phys. Condens. Matter.* 18:S1235–S1255. doi:10.1088/0953-8984/18/28/508

Avdeef, A., K.J. Box, J.E. Comer, C. Hibbert, and K.Y. Tan. 1998. pH-metric logP 10. Determination of liposomal membrane-water partition coefficients of ionizable drugs. *Pharm. Res.* 15:209–215. doi:10.1023/A:101954332221

Bamberg, E., and P. Läuger. 1973. Channel formation kinetics of gramicidin A in lipid bilayer membranes. *J. Membr. Biol.* 11:177–194. doi:10.1007/BF01869820

Baño, M.C., L. Bravo, and C. Abad. 1992. A semi-empirical approach for the simulation of circular dichroism spectra of gramicidin A in a model membrane. *Biophys. J.* 63:70–77. doi:10.1016/S0006-3495(92)81590-4

Berberan-Santos, M.N., E.N. Bodunov, and B. Valeur. 2005. Mathematical functions for the analysis of luminescence decays with underlying distributions I. Kohlrausch decay function (stretched exponential). *Chem. Phys.* 315:171–182. doi:10.1016/j.chemphys.2005.04.006

Bezanilla, F., and C.M. Armstrong. 1977. Inactivation of the sodium channel. I. Sodium current experiments. *J. Gen. Physiol.* 70:549–566. doi:10.1085/jgp.70.5.549

Bruno, M.J., R.E. Koepp II, and O.S. Andersen. 2007. Docosaheaxenoic acid alters bilayer elastic properties. *Proc. Natl. Acad. Sci. USA.* 104:9638–9643. doi:10.1073/pnas.0701015104

Chen, Z., and R.P. Rand. 1998. Comparative study of the effects of several salkanes on phospholipid hexagonal phases. *Biophys. J.* 74:944–952. doi:10.1016/S0006-3495(98)74017-2

de Dios, S.T., K.M. Hannan, R.J. Dilley, M.A. Hill, and P.J. Little. 2001. Troglitazone, but not rosiglitazone, inhibits Na/H exchange activity and proliferation of macrovascular endothelial cells. *J. Diabetes Complications.* 15:120–127. doi:10.1016/S1056-8727(01)00141-6

Deisenhofer, J., O. Epp, I. Sinning, and H. Michel. 1995. Crystallographic refinement at 2.3 Å resolution and refined model of the photosynthetic reaction centre from *Rhodopseudomonas viridis.* *J. Mol. Biol.* 246:429–457. doi:10.1006/jmbi.1994.0097
fluorescence assay. Assay Drug Dev. Technol. 8:427–436. doi:10.1089/adt.2009.0250

Ingólfsson, H.L., R.E. Koeppel II, and O.S. Andersen. 2007. Curcumin is a modulator of bilayer material properties. Biochemistry. 46:10384–10391. doi:10.1021/bi701013n

Ingólfssson, H.L., R.L. Sanford, R. Kapoor, and O.S. Andersen. 2010. Gramicidin-based fluorescence assay for determining small molecules potential for modifying lipid bilayer properties. J. Vis. Exp. 2131. doi:10.3791/2131

Juurink, D.N. 2010. Rosiglitazone and the case for safety over certainty. JAMA. 304:409–471. doi:10.1001/jama.2010.954

Kapoor, R., J.H. Kim, H. Ingólfsson, and O.S. Andersen. 2008. Preparation of artificial bilayers for electrophysiology experiments. J. Vis. Exp. 1033. doi:10.3791/1033

Katsaras, J., R.S. Proser, R.H. Simson, and J.H. Davis. 1992. Constant helical pitch of the gramicidin channel in phospholipid bilayers. Biophys. J. 61:827–830. doi:10.1016/S0006-3495(92)81888-X

Kim, B.Y., C.H. Cho, D.K. Song, K.C. Mun, S.I. Suh, S.P. Kim, D.H. Shin, B.C. Jang, T.K. Kwon, S.D. Cha, et al. 2005. Gilgitizone inhibits its cell proliferation in human uterine leiomyoma via activation of store-operated Ca2+ channels. Am. J. Physiol. Cell Physiol. 288:C389–C395. doi:10.1152/ajpcell.01154.2004

Kock, G.A., S.K. Mishra, and P.I. Aaronson. 1999. Differential effects of insulin-sensitizers troglitazone and rosiglitazone on ion currents in rat vascular myocytes. Eur. J. Pharmacol. 368:103–109. doi:10.1016/S0044-2991(99)00205-0

Le Blanc, O.H. Jr. 1969. Tetraphenylborate conductance through lipid bilayer membranes. Biochim. Biophys. Acta. 193:350–360. doi:10.1016/0006-3495(69)90195-3

Lee, A.G. 2004. How lipids affect the activities of integral membrane proteins. Biochim. Biophys. Acta. 1666:62–87. doi:10.1016/j.jbba.2004.05.012

Lee, K., T. Ibbotson, P.J. Richardson, and P.R. Boden. 1996. Inhibition of KATP channel activity by troglitazone in CRI-G1 insulin-secreting cells. Eur. J. Pharmacol. 313:163–167. doi:10.1016/0014-2999(96)00319-X

Lescon, F.D., and B. Springthorpe. 2007. The influence of drug-ligand concepts on decision-making in medicinal chemistry. Nat. Rev. Drug Discov. 6:881–890. doi:10.1038/nrd2445

Lipinski, C.A., F. Lombardo, B.W. Dominy, and P.J. Feeney. 2001. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Deliv. Rev. 46:3–26. doi:10.1016/S0169-409X(00)00290-9

Lundbæk, J.A. 2008. Lipid bilayer-mediated regulation of ion channel function by amphiphilic drugs. J. Gen. Physiol. 131:421–429. doi:10.1085/jgp.200709948

Lundbæk, J.A., and O.S. Andersen. 1990. Kinetics of gramicidin channel formation in lipid bilayers: transmembrane monomer association. Science. 250:1256–1259. doi:10.1126/science.1709867

Partenskii, M.B., and P.C. Jordan. 2002. Membrane deformation and the elastic energy of insertion: perturbation of membrane elastic constants due to peptide insertion. J. Gen. Physiol. 119:10768–10776. doi:10.1063/1.1519840

Peitzsch, R.M., and S. McLaughlin. 1993. Binding of acylated peptides and fatty acids to phospholipid vesicles: pertinence to myristoylated proteins. Biochemistry. 32:10436–10443. doi:10.1021/bi00090a020

Preininger, K., H. Stingl, R. Englisch, C. Fünnsinn, J. Graf, W. Waldhäusl, and M. Roden. 1999. Acute troglitazone action in isolated perfused rat liver. Br. J. Pharmacol. 126:372–378. doi:10.1038/sj.bjp.0702318

Requena, J., D.A. Haydon, and S.B. Hladky. 1975. Letter: lenses and the compression of black lipid membranes by an electric field. Biophys. J. 15:77–81. doi:10.1016/S0006-3495(75)85793-6

Rossotti, F.J., and H. Rossoti. 1961. The Determination of Stability Constants and Other Equilibrium Constants in Solution. McGraw-Hill, New York. 425 pp.
Bilayer-modifying effects of thiazolidinediones

Sarafidis, P.A. 2008. Thiazolidinedione derivatives in diabetes and cardiovascular disease: an update. *Fundam. Clin. Pharmacol.* 22:247–264. doi:10.1111/j.1472-8206.2008.00568.x

Scheen, A.J. 2001. Thiazolidinediones and liver toxicity. *Diabetes Metab.* 27:305–313.

Seddon, A.M., D. Casey, R.V. Law, A. Gee, R.H. Templer, and O. Ces. 2009. Drug interactions with lipid membranes. *Chem. Soc. Rev.* 38:2509–2519. doi:10.1039/b813853m

Seddon, J.M. 1990. Structure of the inverted hexagonal (H$_3$) phase, and non-lamellar phase transitions of lipids. *Biochim. Biophys. Acta.* 1051:1–69.

Seeman, P. 1972. The membrane actions of anesthetics and tranquilizers. *Pharmacol. Rev.* 24:583–655.

Snow, K.L., and R.H. Moseley. 2007. Effect of thiazolidinediones on bile acid transport in rat liver. *Life Sci.* 80:732–740. doi:10.1016/j.lfs.2006.11.001

Sychev, S.V., L.I. Barsukov, and V.T. Ivanov. 1993. The double $\pi$ $\pi^*$ helix of gramicidin A predominates in unsaturated lipid membranes. *Eur. Biophys. J.* 22:279–288. doi:10.1007/BF00180262

Spector, A.A., and M.A. Yorek. 1985. Membrane lipid composition and cellular function. *J. Lipid Res.* 26:1015–1035.

Stowers, M.A., A.L. van Wijckhuijse, J.C. Marijnissen, B. Scarlett, B.L. van Baar, and C.E. Kientz. 2000. Application of matrix-assisted laser desorption/ionization to on-line aerosol time-of-flight mass spectrometry. *Rapid Commun. Mass Spectrom.* 14:829–833. doi:10.1002/(SICI)1097-0231(20000530)14:10<829::AID-RCM513>3.0.CO;2-3

Sychev, S.V., L.I. Barsukov, and V.T. Ivanov. 1993. The double $\pi$ $\pi^*$ helix of gramicidin A predominates in unsaturated lipid membranes. *Eur. Biophys. J.* 22:279–288. doi:10.1007/BF00180262

Spector, A.A., and M.A. Yorek. 1985. Membrane lipid composition and cellular function. *J. Lipid Res.* 26:1015–1035.

Stowers, M.A., A.L. van Wijckhuijse, J.C. Marijnissen, B. Scarlett, B.L. van Baar, and C.E. Kientz. 2000. Application of matrix-assisted laser desorption/ionization to on-line aerosol time-of-flight mass spectrometry. *Rapid Commun. Mass Spectrom.* 14:829–833. doi:10.1002/(SICI)1097-0231(20000530)14:10<829::AID-RCM513>3.0.CO;2-3

Sychev, S.V., L.I. Barsukov, and V.T. Ivanov. 1993. The double $\pi$ $\pi^*$ helix of gramicidin A predominates in unsaturated lipid membranes. *Eur. Biophys. J.* 22:279–288. doi:10.1007/BF00180262

Tori, H., K. Yoshida, T. Tsukamoto, and S. Tanayama. 1984. Disposition in rats and dogs of ciglitazone, a new antidiabetic agent. *Xenobiotica.* 14:259–268. doi:10.3109/00498258409151410

Turner, D.C., and S.M. Gruner. 1992. X-ray diffraction reconstruction of the inverted hexagonal (H$_3$) phase in lipid-water systems. *Biochemistry.* 31:1340–1355. doi:10.1021/bi00126a009

Veatch, W.R., R. Mathies, M. Eisenberg, and L. Stryer. 1975. Simultaneous fluorescence and conductance studies of planar bilayer membranes containing a highly active and fluorescent analog of gramicidin A. *J. Mol. Biol.* 99:75–92. doi:10.1016/S0022-2836(75)80160-4

Wallace, B.A., W.R. Veatch, and E.R. Blout. 1981. Conformation of gramicidin A in phospholipid vesicles: circular dichroism studies of effects of ion binding, chemical modification, and lipid structure. *Biochemistry.* 20:5754–5760. doi:10.1021/bi00523a018

Wendt, D.J., C.F. Starmer, and A.O. Grant. 1992. Na channel kinetics remain stable during perforated-patch recordings. *Am. J. Physiol.* 263:C1234–C1240.

Wenk, M.R., T. Alt, A. Seelig, and J. Seelig. 1997. Octyl-beta-D-glucopyranoside partitioning into lipid bilayers: thermodynamics of binding and structural changes of the bilayer. *Biophys. J.* 72:1719–1731. doi:10.1016/S0006-3495(97)78818-0

White, S.H. 1974. Letter: comments on “electrical breakdown of bimolecular lipid membranes as an electromechanical instability”. *Biophys. J.* 14:155–158. doi:10.1016/S0006-3495(74)70007-8

White, S.H., and T.E. Thompson. 1973. Capacitance, area, and thickness variations in thin lipid films. *Biochim. Biophys. Acta.* 323:7–22. doi:10.1016/0005-2736(73)90428-8

White, S.H., W.C. Wimley, A.S. Ladokhin, and K. Hristova. 1998. Protein folding in membranes: determining energetics of peptide-bilayer interactions. *Methods Enzymol.* 295:62–87. doi:10.1016/S0076-6879(98)50535-2

Xue, Y.J., J.C. Turner, J.B. Meeker, J. Pursley, M. Arnold, and S. Unger. 2003. Quantitative determination of pioglitazone in human serum by direct-injection high-performance liquid chromatography mass spectrometry and its application to a bioequivalence study. *J. Chromatogr. B Analyt. Technol. Biomed. Life Sci.* 795:215–226. doi:10.1016/S1570-0232(03)00575-0

Zhelev, D.V. 1998. Material property characteristics for lipid bilayers containing lysolipid. *Biophys. J.* 75:321–330. doi:10.1016/S0006-3495(98)77516-2

Zhou, Y., and R.M. Raphael. 2005. Effect of salicylate on the elasticity, bending stiffness, and strength of SOPC membranes. *Biophys. J.* 89:1789–1801. doi:10.1529/biophysj.104.05410

Zingheim, H.P., and E. Neher. 1974. The equivalence of fluctuation analysis and chemical relaxation measurements: a kinetic study of ion pore formation in thin lipid membranes. *Biophys. Chem.* 2:197–207. doi:10.1016/0301-4622(74)80045-1